Abstract
In this issue of Cancer Discovery, Sodir and colleagues employ a pancreatic ductal adenocarcinoma mouse model with mutant KRAS and inducible MYC to demonstrate that MYC acts as a reversible driver of malignant tumor progression. Abrogation of MYC triggers rapid regression and disassembly of the ensemble tumor through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms, providing a compelling rationale for therapeutic targeting of MYC.
Original language | English (US) |
---|---|
Pages (from-to) | 495-497 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 10 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2020 |
ASJC Scopus subject areas
- Oncology